REC-4881 for Solid Tumors

Recruiting in Palo Alto (17 mi)

+68 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Recursion Pharmaceuticals Inc.

No Placebo Group

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.

Eligibility Criteria

This trial is for adults with advanced solid tumors that can't be removed by surgery and have specific gene mutations (AXIN1 or APC). If they have colorectal cancer, it must not involve RAS/RAF mutations. Participants should have tried standard treatments without success or cannot tolerate them, and must be relatively active and able to care for themselves.

Inclusion Criteria

I am fully active and can carry on all pre-disease activities without restriction.

I am 18 or older with a specific type of advanced cancer that cannot be surgically removed.

My cancer has worsened or returned after treatment, or I can't tolerate standard cancer treatments.

+1 more

Participant Groups

The study tests REC-4881, a drug taken orally at a dose of 12 mg daily. It aims to evaluate its safety, effectiveness, and how the body processes it in patients with certain genetic mutations who have advanced solid tumors.

2Treatment groups

Experimental Treatment

Group I: AXIN1 CohortExperimental Treatment1 Intervention

Participants will receive REC-4881 12mg PO dosed QD

Group II: APC CohortExperimental Treatment1 Intervention

Participants will receive REC-4881 12mg PO dosed QD

REC-4881 is already approved in United States for the following indications:

🇺🇸 Approved in United States as REC-4881 for: